Entering text into the input field will update the search result below

Biomerica teams up with UT Houston to test irritable bowel syndrome therapy

  • Biomerica (NASDAQ:BMRA) has signed a definitive agreement with the University of Texas Health Science Center at Houston (UTH) to join the clinical trial for Biomerica’s new InFoods diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. UTH can now begin enrollment of patients in this trial.
  • A clinical lab version of the InFoods IBS DGT product is being used in this clinical trial. The current endpoint trial is expected to be completed in approx. 6 months. However, Biomerica plans to commence the final pivotal trial several months thereafter.
  • The endpoint trial stratifies enrollment by the three main IBS subclasses (IBS-Constipation, IBS-Diarrhea and IBS-Mixed). The clinical study design has already received a non-significant risk determination from the FDA.

Recommended For You

About BMRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BMRA--
Biomerica, Inc.